首页> 美国卫生研究院文献>other >Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

【2h】

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

机译：表皮生长因子受体（EGFR）通路生物标志物在厄洛替尼的III期随机试验与观察的卵巢癌患者中无一线铂类化学疗法后疾病进展的证据

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundIn this work, we aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarkers in patients with ovarian cancer who were treated within the phase III randomized European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG) 55041 study comparing erlotinib with observation in patients with no evidence of disease progression after first-line platinum-based chemotherapy.

机译：背景在这项工作中，我们旨在确定在欧洲癌症-妇科癌症研究与治疗组织（EORTC-GCG）55041研究的III期随机治疗中接受治疗的卵巢癌患者中的分子表皮生长因子受体（EGFR）组织生物标记物将一线铂类化疗后无疾病进展迹象的患者中的厄洛替尼与观察结果进行比较。

著录项

期刊名称 other
作者
Evelyn Despierre; Ignace Vergote; Ryan Anderson; Corneel Coens; Dionyssios Katsaros; Fred R. Hirsch; Bram Boeckx; Marileila Varella-Garcia; Annamaria Ferrero; Isabelle Ray-Coquard; Els M. J. J. Berns; Antonio Casado; Diether Lambrechts; Antonio Jimeno;
展开▼
作者单位

展开▼
年(卷),期 -1(10),4
年度 -1
页码 583–596
总页数 22
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015) [J] . Despierre Evelyn, Vergote Ignace, Anderson Ryan, Targeted oncology . 2016,第3期

机译：表皮生长因子受体（EGFR）途径生物标志物在厄洛替尼的III期随机试验中与在无一线铂类化学疗法后无疾病进展迹象的卵巢癌患者中观察到的比较（第10卷，第583页，2015年）
2. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy [J] . Despierre Evelyn, Vergote Ignace, Anderson Ryan, Targeted oncology . 2015,第4期

机译：表皮生长因子受体（EGFR）通路生物标志物在厄洛替尼的随机III期临床试验中与对一线铂类化学疗法一线治疗后无疾病进展证据的卵巢癌患者进行观察
3. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. [J] . Ignace B Vergote, Antonio Jimeno, Florence Joly, Journal of Clinical Oncology . 2014,第4期

机译：欧洲癌患者患者欧洛替尼对患者患者的随机期III研究 - 卵巢癌化疗患者：欧洲癌症 - 妇科癌症组的研究和治疗组织，妇科癌症杂交研究。
4. Effect of preoperative cancer treatment on epidermal growth factor receptor (EGFR) receptor expression level in ABY-029 guided sarcoma surgery [C] . Xiaochun Xu, Kimberley S Samkoe, Eric R. Henderson Society of Photo-Optical Instrumentation Engineers;Conference on Molecular-Guided Surgery: Molecules, Devices, and Applications . 2020

机译：术前癌症治疗对ABY-029导向肉瘤手术中表皮生长因子受体（EGFR）受体表达水平的影响
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials [O] . Yoshikazu Hasegawa, Masahiko Ando, Makoto Maemondo, 2015

机译：吸烟状态在非小细胞肺癌患者无进展生存中的作用该患者具有接受一线EGFR酪氨酸激酶抑制剂对铂类双重化疗的活化表皮生长因子受体（EGFR）突变：前瞻性随机试验的Meta分析。
7. Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy [O] . Despierre, Evelyn, Vergote, Ignace, Anderson, Ryan, 2016

机译：勘误至：厄洛替尼的III期随机临床试验与表皮生长因子受体（EGFR）通路生物标志物对比在没有一线铂类化学疗法一线治疗的卵巢癌患者中的观察

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

摘要

著录项

相似文献

相关主题

期刊订阅